News

ProMIS Neurosciences Technologies Hold Promise for New Alzheimer’s Therapy

ProMIS Neurosciences reported progress of drug discovery technologies at the recent Alzheimer’s Association International Conference (AAIC) meeting, held in Toronto, Canada, showing that the technologies specifically target certain forms of amyloid-beta and tau in Alzheimer’s disease. The company works to identify structures on the surface of the toxic variants of…

CaringKind, Cure Alzheimer’s Fund Establish Alliance in New York

CaringKind, New York’s leading organization in caring for Alzheimer’s disease and dementia patients for the past 30 years, has established an alliance with Cure Alzheimer’s Fund, a not-for-profit organization funding research to prevent, stop, or reverse the neurodegenerative disease. With the new alliance, people who contact CaringKind to find…

Quest Diagnostics Launches Digital Tool, CogniSense, to Assess Dementia

Quest Diagnostics has announced the release of CogniSense, its digital cognitive assessment tool to assist physicians in diagnosing, assessing, and managing the care of people with cognitive dysfunction. Quest says its design objective for CogniSense was to overcome the various limitations inherent in conventional, paper-based cognitive assessment, such as…

Actinogen Reveals Promising Data on Alzheimer’s Therapy at AAIC 2016, Readies Phase 2 Trial

Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain…

Cognitive Decline in Mild Alzheimer’s Slowed with Azeliragon

Data from a Phase 2b clinical trial showing that  vTv Therapeutics‘s investigational drug, azeliragon, slows cognitive decline in patients with mild Alzheimer’s disease were presented at the Alzheimer’s Association International Conference 2016 in Toronto this week. Azeliragon is a drug that blocks the receptor RAGE (Receptor for Advanced Glycation Endproducts) in…

‘Monster in the Mind’ – Brilliantly Crafted Alzheimer’s Film Overturns Doomsday Predictions

On July 26, a different kind of happening interrupted the usual bustle of activity at this year’s Alzheimer’s Association International Conference (AAIC 2016) in Canada. Attending scientists became the first viewers (at a sneak-peek preview before the North American premiere) of a new kind of full-length documentary film — one that reveals untold…